Stem Cell Transplantation

Transplant with an expanded ECT-001 cord blood for Blood Cancers

Phase 2
Led By Sandra Cohen, MD
Research Sponsored by Ciusss de L'Est de l'Île de Montréal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up3 years
Awards & highlights
No Placebo-Only Group

Study Summary

This trial is testing a new way to expand cord blood cells so that they can be used in a stem cell transplant. This is important because cord blood transplants are associated with a lower risk of relapse, especially in the presence of minimal residual disease, and a low risk of chronic graft versus host disease. However, cord blood transplants are hampered by a higher risk of transplant related mortality when compared to bone marrow/peripheral blood transplants because of the limited cell dose of cord blood. The UM171 expansion protocol has proven to be technically feasible and safe in a previous trial and is associated with a low risk of transplant related mortality and graft versus

Eligible Conditions
  • High Risk Blood Cancers
  • Cord Blood Transplant


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall survival (OS)
Relapse Free survival (RFS)
Transplant Related Mortality (TRM)
Secondary outcome measures
Adverse events grade 3 or higher
Graft failure
Hospitalization events
+6 more
Other outcome measures
Graft composition and evaluation
Identify markers suggesting escape from the immune system
Immune reconstitution

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Main interventionExperimental Treatment1 Intervention
Eligible patients will receive an ablative conditioning regimen and be infused with an ECT-001 expanded cord-blood. The ECT-001 expanded CB could be infused fresh, or cryopreserved.

Find a site

Who is running the clinical trial?

Ciusss de L'Est de l'Île de MontréalLead Sponsor
64 Previous Clinical Trials
5,101 Total Patients Enrolled
Stem Cell NetworkOTHER
7 Previous Clinical Trials
536 Total Patients Enrolled
ExCellThera inc.Industry Sponsor
4 Previous Clinical Trials
62 Total Patients Enrolled

Media Library

Transplant with an expanded ECT-001 cord blood (Stem Cell Transplantation) Clinical Trial Eligibility Overview. Trial Name: NCT03913026 — Phase 2
Blood Cancers Research Study Groups: Main intervention
Blood Cancers Clinical Trial 2023: Transplant with an expanded ECT-001 cord blood Highlights & Side Effects. Trial Name: NCT03913026 — Phase 2
Transplant with an expanded ECT-001 cord blood (Stem Cell Transplantation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03913026 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA given its endorsement to utilizing ECT-001 cord blood for transplantation?

"Data from Phase 2 trials suggest that Transplant with an expanded ECT-001 cord blood is safe, so this intervention received a score of 2."

Answered by AI

Are there any vacancies open to prospective participants in this clinical trial?

"As per the details on, this research project is currently open to new participants. The trial was initiated in April of 2019 and last updated in August 2021."

Answered by AI

What is the current patient population for this clinical investigation?

"Affirmative. According to, this trial is actively looking for people to participate in the study which was initially posted on April 1st 2019 and had its latest update on August 2nd 2021. 20 individuals need to be recruited from a single medical centre."

Answered by AI

Does the age bracket of this trial encompass those greater than two decades old?

"This clinical trial is open to patients aged 18 and above, with the upper limit for enrollment set at 70 years old."

Answered by AI

Is participation in this research trial open to me?

"To participate in this trial, individuals must have undergone a cord blood transplant and be between 18-70 years of age. Currently, the research team is looking to recruit approximately 20 people."

Answered by AI
~0 spots leftby Dec 2023